title: Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA.
abstract: With the approval of two grass tablets and one ragweed tablet for sublingual immunotherapy (SLIT) by the US FDA in April 2014, the practice of allergy immunotherapy (AIT) in the USA has dramatically changed. Until this time, there were no approved allergen extracts for sublingual administration and physicians who prescribed SLIT for their patients did so without full knowledge of proper dosing or assurance of its safety. Now sublingual allergen tablets are available that have proven safe and effective doses. This article describes, in detail, the studies that have been conducted with a timothy grass SLIT tablet and draws some comparisons to the alternative 5-grass SLIT tablet. It also attempts to predict what will be the impact of the introduction of these tablets on the practice of AIT in the USA over the next few years.
authors.affiliation: National Jewish Health, 1400 Jackson St, Denver, CO 80206, USA.
authors.forename: Harold S
authors.initials: HS
authors.lastname: Nelson
mesh_terms: D000286:Administration, Sublingual; D006801:Humans; D031784:Phleum / Q000737:chemistry*; D010936:Plant Extracts / Q000737:chemistry / Q000627:therapeutic use*; D065631:Rhinitis, Allergic / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D063729:Sublingual Immunotherapy; D014481:United States
chemical_list: C551013:Grazax; D010936:Plant Extracts
keywords: AIT; SCIT; SLIT; allergy immunotherapy; grass immunotherapy; subcutaneous immunotherapy; sublingual immunotherapy